Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

ll year 2009 was $48.7 million, compared with $48.2 million in 2008.  Total revenue for 2009 reflects higher revenue from the collaboration with Roche for the development of protease inhibitors.  Collaboration revenue in 2009 included a $20.0 million milestone in connection with the initiation of the Phase 2b study of RG7227.  Collaboration revenue in 2008 included a $15.0 million development milestone payment from Roche.

Research and development (R&D) expenses in the fourth quarter of 2009 were $21.2 million compared with $26.2 million in the fourth quarter of 2008.  R&D expenses were $89.1 million for the 12 months ended December 31, 2009, compared with $104.2 million in 2008.  Lower R&D expenses in both periods reflect completion of the CAPACITY clinical trials in early 2009, partially offset by increased expenses associated with the RECAP extension study, the Phase 2b study of RG7227 in patients chronically infected with HCV and the preparation of the NDA and MAA for pirfenidone.  

General and administrative (G&A) expenses were $10.6 million in the fourth quarter of 2009, compared with $7.9 million in the same period a year earlier, an increase of 34%.  G&A expenses were $37.5 million in the full year 2009, an increase of 23% from $30.6 million in 2008.  The additional G&A expenses are primarily attributed to costs related to preparation for the potential commercialization of pirfenidone, which is subject to regulatory approvals.

The net loss for the fourth quarter of 2009 was <
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... - Arrowhead,Research Corporation (NASDAQ:ARWR) announced today that,majority-owned ... Proceedings of the National Academy of Sciences,(PNAS) ... use multiple,systemic dosing with Calando's lead siRNA ... technologies in targeted,polymeric delivery systems and siRNA ...
... in Two Most Common Mutations, CRANBURY, N.J., ... biopharmaceutical company developing small,molecule, orally-administered pharmacological chaperones ... genetic diseases, announced today,that it will present ... tartrate, AT2101) for Gaucher disease at,the of ...
Cached Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:5/22/2015)... 2015 Mountain Point Medical Center, a campus ... ceremony on Friday, May 29, 2015 at 11 a.m., followed ... The new medical center, set to officially open on June ... UT 84043. , “The opening of Mountain Point Medical ... Utah County community,” said Kent Loosle, CEO of Mountain Point ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 ... Health IT solutions, announced today that Bill Lane, ... is the developer of BlueEHS,a first of its ... offers a customizable Electronic Health Records (EHR) with ... interfaces, a telemedicine-enabled comprehensive patient portal, and more. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 sweetFrog Enterprises, LLC. ... in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store ... chain was listed as #22 on the Inc. 500 list ... have lived and worked in East Texas for 20 years ... Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog locations. ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... prevention or delay of full-blown disease seen in treated ... Among patients who show early signs of multiple sclerosis, ... halve the risk that they will develop full-blown disease, ... who are diagnosed with multiple sclerosis first show signs ...
... With the thermometer dropping and the onset of flu ... and the public to encourage them to get a seasonal ... supported healthy behaviors and prevention efforts," said Merri Dee, AARP ... protect themselves and those around them by getting vaccinated." , ...
... $30 billion and $34 billion reside in the asbestos ... to pay claims brought by workers who contracted asbestos-related ... Asbestos Litigation Conference" produced in San Francisco by HB ... state court judges from around the country who shared ...
... WASHINGTON, Pa., Oct. 6 RAM Technologies, Inc., ... for health plans, has once again been named ... Tech Employers in the Greater Philadelphia region. ... edge applications that automate the administration of health ...
... While little is known about the causes of glioma, ... this rare but often deadly form of brain cancer ... height. "Our findings suggest that biological factors ... play a role in glioma etiology. This clue could ...
... ... 2009 News Briefs are designed to keep you up-to-date on embargoed studies ... Society of Plastic Surgeons (ASPS) held October 23-27 in Seattle. All briefs ... advance copy of study abstracts, for media registration, or to arrange interviews ...
Cached Medicine News:Health News:Early Drug Treatment May Cut Multiple Sclerosis Risk 2Health News:AARP Encourages All Adults 50+ to Get Flu Vaccine This Season 2Health News:Asbestos Trusts, Asbestos Judges Featured at Two HB Events Dec. 2 & 3 2Health News:RAM Technologies Named to Philadelphia Business Journal's List of Top Tech Employers 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 2Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 4Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 5Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: